Multiple myeloma develops from abnormal plasma cells, the immune cells responsible for producing antibodies. These cancerous cells accumulate in the bone marrow and release large quantities of immunoglobulins, placing exceptional demands on their protein-production machinery. They must continuously fold, transport and maintain vast numbers of proteins while coping with oxidative stress, metabolic pressure and damage to cellular components. Autophagy, a regulated recycling process, helps cells endure these conditions. During autophagy, portions of the cytoplasm, damaged proteins and defective organelles are enclosed in double-membrane structures called autophagosomes. These structures then fuse with lysosomes, where their contents are broken down and recycled.

The new research focuses on ULK3, a member of the Unc-51-like kinase family. Kinases are enzymes that control other proteins by adding phosphate groups to them, thereby changing their activity, location or stability. ULK proteins are widely recognized as early regulators of autophagy, helping cells decide when to initiate the formation of autophagosomes. ULK1 and ULK2 have traditionally received most of the attention in this pathway, while ULK3 has remained less clearly defined. The study now links ULK3 to the biology of multiple myeloma, suggesting that this kinase is not merely a redundant relative of other autophagy regulators but may perform a meaningful function in malignant plasma cells.

The importance of this connection lies in the way myeloma cells use autophagy as a survival strategy. Autophagy is not automatically beneficial or harmful; its effect depends on the cell and its circumstances. In healthy tissues, it can remove damaged mitochondria, eliminate toxic protein aggregates and preserve energy during starvation. In cancer, the same recycling system can help tumor cells tolerate chemotherapy, nutrient deprivation and rapid growth. For plasma-cell cancers, which are burdened by intense protein synthesis, autophagy may be especially valuable because it helps maintain internal quality control and supplies metabolic building blocks when external resources are limited.

According to the study, ULK3 contributes to the ability of multiple myeloma cells to sustain autophagy and remain viable. This finding implies that ULK3 may help coordinate the early steps of the autophagic response or support the broader cellular machinery required to complete it. When such a regulatory node is weakened, cancer cells may lose their capacity to clear damaged material and respond to stress. The result can be an accumulation of defective proteins, impaired organelle function and increased susceptibility to cell death. In myeloma, where the production of abnormal or excessive proteins is already a central feature of the disease, disruption of this balance could be particularly damaging.

The work also offers a biological explanation for why targeting autophagy may affect myeloma survival. Blocking the pathway can produce a form of “stress overload”: cellular waste accumulates, energy production becomes less efficient and damaged components remain in the cytoplasm. At the same time, cancer cells may be unable to reduce their protein burden or adapt to hostile conditions. ULK3 therefore represents a potential control point before the later stages of autophagosome formation and lysosomal degradation. Targeting an early regulator could, in principle, interrupt the process before malignant cells can activate several downstream protective mechanisms.

However, the study does not imply that ULK3 is a universal cancer switch or that a single intervention will eliminate multiple myeloma. Autophagy is a complex network with overlapping regulators, feedback loops and cell-specific effects. If one ULK family member is inhibited, cancer cells may compensate through alternative signaling routes, including pathways controlled by ULK1, ULK2, nutrient-sensing complexes or stress-responsive kinases. The therapeutic challenge will be to determine whether ULK3 can be blocked selectively enough to harm myeloma cells without causing unacceptable injury to normal tissues that also depend on autophagy for long-term maintenance.

The findings are especially relevant to the search for treatments that can overcome drug resistance. Modern myeloma therapy commonly combines agents that attack different aspects of plasma-cell biology, yet many patients eventually relapse because residual malignant cells adapt and survive. A therapy directed at ULK3 could potentially be evaluated alongside established treatments, with the goal of preventing cancer cells from using autophagy as a backup survival program. Such combinations would require careful testing, because some drugs may increase cellular stress and thereby make autophagy inhibition more powerful, while others could trigger compensatory responses that reduce its effect.

Before ULK3 can become a clinical target, researchers will need to clarify how its activity is controlled, which molecular partners it engages and whether its dependence is strongest in particular genetic or metabolic subtypes of myeloma. Biomarkers will also be essential. Measuring ULK3 abundance or activity alone may not predict response if the pathway is governed by several interacting proteins. Investigators may instead need to examine autophagic flux—the rate at which cellular material moves through the pathway—along with protein-folding stress, mitochondrial condition and the molecular features of each patient’s tumor. The study’s central message is therefore both mechanistic and practical: ULK3 helps myeloma cells survive, and understanding that dependence could reveal a new route for weakening a disease that remains difficult to cure.

Subject of Research: Unc-51-like kinase 3 (ULK3), autophagy, cell survival and multiple myeloma

Article Title: Unc-51 like kinase 3 (ULK3) contributes to autophagy and cell survival in multiple myeloma

Article References: Tauro, M., Li, T., Sudalagunta, P.R. et al. “Unc-51 like kinase 3 (ULK3) contributes to autophagy and cell survival in multiple myeloma.” Nature Communications (2026). https://doi.org/10.1038/s41467-026-76711-0

Image Credits: AI Generated

DOI: 10.1038/s41467-026-76711-0

Keywords: ULK3, autophagy, multiple myeloma, plasma cells, cancer cell survival, cellular stress, kinase signaling, therapeutic targets

Osteoarthritis represents a multifactorial pathology characterized by the progressive deterioration of articular cartilage and synovial inflammation, leading to chronic pain and decreased joint mobility. Conventional therapeutic modalities largely focus on symptom palliation through analgesics and non-steroidal anti-inflammatory drugs (NSAIDs), which provide transient relief without halting disease progression. The absence of effective disease-modifying interventions compels the need for advanced materials capable of addressing the multifaceted pathophysiology intrinsic to OA. The di-selenide hydrogel microspheres, developed with precise synthetic techniques, represent an elegant solution that bridges this therapeutic gap.

The core innovation lies in the incorporation of organic di-selenide linkages within a hydrogel matrix fashioned into microspheres, enabling a sustained and controlled release of therapeutic agents with intrinsic antioxidative and anti-inflammatory properties. Selenium, an essential trace element, has a long-recognized role in redox homeostasis and cellular protection against reactive oxygen species (ROS), which are abundantly generated during OA progression. By covalently embedding di-selenide bonds within the hydrogel’s polymeric network, these microspheres leverage selenium’s biological activity for continuous ROS scavenging, effectively interrupting oxidative stress cascades that exacerbate tissue damage in affected joints.

Beyond oxidative stress mitigation, the hydrogel microspheres provide a biomechanically favorable scaffold that facilitates chondrocyte proliferation and extracellular matrix production. The water-retentive, viscoelastic properties of the hydrogel mimic the native cartilage microenvironment, thus supporting cellular viability and promoting tissue regeneration at the defect site. Furthermore, the material is engineered for biodegradability and injectability, making it amenable to minimally invasive intra-articular administration, which is critical for clinical translation and patient compliance.

The multimodal therapeutic strategy embodied by these microspheres extends to their anti-inflammatory effects, which are mediated not only by the inherent properties of selenium but also through the strategic encapsulation of bioactive molecules aimed at modulating synovial inflammation. This dual-action approach is significant given that synovial inflammation contributes to cartilage degradation through the release of catabolic enzymes and pro-inflammatory cytokines. By tempering inflammatory responses at the joint synovium, the treatment preserves cartilage integrity and reduces pain sensations, thus improving functional outcomes.

Detailed physicochemical characterization of the hydrogel microspheres reveals a uniform size distribution optimal for intra-articular retention and tissue penetration. The di-selenide bonds confer dynamic covalent reversibility, an attribute that allows the hydrogel to respond adaptively to the joint’s oxidative microenvironment, facilitating on-demand release of therapeutic agents. This stimuli-responsive behavior distinguishes the system from conventional hydrogels, which often lack specificity and tend to degrade indiscriminately, limiting therapeutic efficacy.

Animal models of osteoarthritis have demonstrated pronounced benefits following treatment with these organic di-selenide hydrogel microspheres. Histological analyses show enhanced cartilage thickness and reduced synovial inflammation relative to controls treated with conventional NSAIDs or non-functionalized hydrogels. Importantly, functional assays measuring joint mobility and pain thresholds confirm the microspheres’ ability to restore physiological joint function, highlighting their potential as a disease-modifying intervention rather than solely a symptomatic treatment.

In addition to biocompatibility and efficacy, the safety profile of the microspheres has been rigorously evaluated, with no detectable toxicity or adverse immune responses observed during extended in vivo studies. This represents a critical milestone, as selenium’s bioavailability and therapeutic window must be carefully managed to avoid systemic toxicity. The covalent integration of selenium within the hydrogel network appears to mitigate these risks by localizing its activity within the joint microenvironment.

From a translational perspective, the researchers underscore the scalability and reproducibility of their synthetic protocol, utilizing commercially viable polymers and facile chemical modifications. This pragmatic consideration accelerates the pathway toward clinical trials and eventual commercialization. Furthermore, the injectable format of the hydrogel microspheres aligns with current orthopedic practices, facilitating seamless integration into existing treatment workflows without necessitating complex surgical interventions.

The innovation extends implications beyond osteoarthritis, as the modular design of the hydrogel platform allows customization for other chronic inflammatory and degenerative disorders characterized by oxidative stress and tissue degradation. Rheumatoid arthritis, intervertebral disc degeneration, and even certain neurodegenerative conditions might benefit from tailored iterations of this material, potentially broadening its clinical impact significantly.

Intensive mechanistic studies detailed in the publication elucidate the interplay between the di-selenide bond dynamics and cellular signaling pathways implicated in chondroprotection and inflammation resolution. Key molecular markers such as nuclear factor erythroid 2-related factor 2 (Nrf2) activation and suppression of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) are modulated by the hydrogel treatment, providing a molecular rationale for its observed therapeutic outcomes. Such insights offer valuable guidance for the rational design of next-generation biomaterials for musculoskeletal applications.

This research exemplifies the convergence of material science, organic chemistry, and biomedical engineering to address a critical public health challenge. The deployment of selenium’s unique chemistry within a sophisticated hydrogel architecture not only reflects scientific creativity but also a deep commitment to improving patient quality of life in osteoarthritis—a disease often associated with disability and diminished independence in the aging population.

Looking ahead, the team envisions integrating this hydrogel platform with advanced diagnostic modalities for real-time monitoring of joint health post-injection. Incorporating imaging agents or biosensors within the microspheres could enable clinicians to dynamically track therapeutic efficacy and tailor dosing schedules, ushering in a new era of personalized medicine for osteoarthritis.

In conclusion, the organic di-selenide hydrogel microspheres developed by Liu and colleagues represent a paradigm shift in osteoarthritis treatment by synergistically targeting oxidative stress, inflammation, and tissue regeneration through a sophisticated, injectable biomaterial. This innovation paves the way for durable, disease-modifying therapies that not only alleviate symptoms but also restore joint function and integrity. As clinical validation progresses, this approach may transform the management of osteoarthritis and inspire new biomaterial-based interventions across a spectrum of degenerative diseases.

Subject of Research: Organic di-selenide hydrogel microspheres for treatment of osteoarthritis.

Article Title: Organic di-selenide hydrogel microspheres for multimodal treatment of osteoarthritis.

Article References:

Liu, Y., Zhang, Y., Yu, C. et al. Organic di-selenide hydrogel microspheres for multimodal treatment of osteoarthritis. Nat Commun (2026). https://doi.org/10.1038/s41467-026-68817-2

Image Credits: AI Generated

Diabetic periodontitis, a severe complication in patients with uncontrolled diabetes, is characterized by chronic inflammation, oxidative stress, and irreversible bone loss around teeth. Traditional treatments have often fallen short in reversing these pathological changes, largely due to the intricate interplay between oxidative stress and impaired bone regeneration. The novel approach utilizing antler stem cell-derived exosomes offers a dual mechanism of action, precisely targeting these pathological hallmarks.

At the cellular level, exosomes are extracellular vesicles secreted by many cell types that facilitate intercellular communication by transferring proteins, lipids, and nucleic acids. The researchers isolated these vesicles specifically from antler stem cells, which are known for their remarkable regenerative capacity due to the aggressive and rapid growth of deer antlers. By leveraging the inherent biological potency of these exosomes, the study aimed to test their efficacy in neutralizing ROS and fostering new bone formation.

The research team used a rat model with experimentally induced diabetic periodontitis to closely mimic the human disease condition. The rats demonstrated characteristic signs of increased oxidative stress and alveolar bone loss, making them ideal candidates to evaluate the efficacy of the exosomal therapy. Upon administration, the exosomes facilitated a significant reduction in ROS levels, which ordinarily exacerbate tissue damage and inflammatory responses. This antioxidant role is pivotal because oxidative stress is a major driver of periodontal degradation in diabetic patients.

Additionally, the study demonstrated that the antler stem cell-derived exosomes enhanced osteogenesis—the process by which new bone is formed. Bone regeneration in periodontitis is notoriously difficult due to the chronic inflammatory microenvironment that impairs the differentiation and function of osteoblasts. The vesicles appear to stimulate osteoprogenitor cells and modulate inflammatory mediators, thereby creating a conducive environment for bone repair. This finding underscores the therapeutic promise of exosome-based interventions for reversing bone loss associated with chronic periodontal disease.

One of the remarkable aspects of this research lies in its ability to integrate anti-inflammatory and antioxidant effects with regenerative processes. The exosomes not only suppress detrimental free radicals but also activate signaling pathways that promote tissue regeneration. This dual-action approach could potentially lead to more effective clinical outcomes compared to therapies that only focus on controlling infection or inflammation.

Mechanistically, the study revealed that the exosomes carried a cargo of microRNAs and proteins critical to cellular antioxidant responses and bone metabolism. These bioactive molecules influenced key signaling networks such as the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, which regulates cellular defense against oxidative damage. Activation of Nrf2 resulted in the upregulation of antioxidant enzymes, tipping the balance away from oxidative stress toward tissue preservation and regeneration.

From a translational perspective, the use of antler stem cell-derived exosomes presents a novel and potentially safer therapeutic avenue as opposed to cell transplantation. Exosome therapy circumvents many of the risks associated with stem cell therapies, including immune rejection and tumorigenicity, while maintaining the ability to modulate the cellular environment favorably. This approach reflects an emerging paradigm in regenerative medicine focused on cell-free strategies.

Moreover, the study’s findings could impact not only diabetic periodontitis but also other diseases characterized by oxidative stress and bone loss, such as osteoporosis and rheumatoid arthritis. The inherent antioxidative and osteogenic properties of these exosomes provide a versatile platform for future therapeutic development in musculoskeletal medicine.

The researchers noted the importance of further investigations to optimize exosome dosage, delivery methods, and long-term safety profiles before clinical trials in humans can be initiated. Nonetheless, the current findings represent a significant milestone in periodontal and regenerative medicine, offering hope for millions suffering from diabetes-related oral complications.

The implications of this research extend beyond therapy to diagnostic applications. Exosomes can serve as biomarkers for disease progression and treatment response, given their reflective molecular cargo of parental cells. Understanding these exosomal signatures could pave the way for personalized medicine approaches in managing diabetic periodontitis and similar inflammatory bone diseases.

In conclusion, the study by Guo, Ren, Libonati, and colleagues is a seminal contribution that demonstrates the restorative potential of antler stem cell-derived exosomes in diabetic periodontitis. By effectively scavenging ROS and promoting osteogenesis, these exosomes restore periodontal homeostasis, presenting a novel therapeutic strategy that merges the advantages of natural regenerative cues with modern biomedical technology. This approach holds promise not only for dental medicine but also for broader applications in tissue engineering and regenerative therapies.

As the scientific community continues to explore the multifaceted roles of exosomes, their utility in addressing complex systemic and localized pathologies will undoubtedly expand. This pioneering work stands as a testament to the power of nature-inspired solutions in advancing human health and combating chronic debilitating diseases.

Future research directions outlined by the authors include exploring the molecular mechanisms underlying exosome-mediated immunomodulation and bone repair in diabetic environments, as well as integrating exosome therapy with current periodontal treatment modalities to enhance efficacy and clinical outcomes. Such multidisciplinary efforts will accelerate the transition from bench to bedside, revolutionizing the management of diabetes-related periodontal destruction.

This discovery also invites a reevaluation of stem cell-derived exosome sources, highlighting antler stem cells as a uniquely potent reservoir for regenerative factors. Considering the regenerative ability of antlers, exosomes from this source might harbor novel biomolecules absent in other cell types, offering unexpected therapeutic benefits.

Ultimately, this study reinforces the critical role of oxidative stress in diabetic complications and positions antioxidant strategies alongside regenerative medicine as a next-generation approach to treatment. The convergence of these fields, exemplified by antler stem cell-derived exosomes, marks an exciting chapter in biomedical research with profound clinical implications for millions worldwide.

Subject of Research: Therapeutic effects of antler stem cell-derived exosomes on diabetic periodontitis, focusing on ROS scavenging and osteogenesis in a rat model.

Article Title: Antler stem cell-derived exosomes restore periodontal homeostasis in a rat model with diabetic periodontitis through enhancing ROS scavenging and osteogenesis.

Article References:
Guo, Q., Ren, S., Libonati, A. et al. Antler stem cell-derived exosomes restore periodontal homeostasis in a rat model with diabetic periodontitis through enhancing ROS scavenging and osteogenesis. Cell Death Discov. 11, 500 (2025). https://doi.org/10.1038/s41420-025-02800-6

Image Credits: AI Generated

DOI: 10.1038/s41420-025-02800-6

The TCA cycle, often referred to as the Krebs cycle or citric acid cycle, is a central metabolic pathway through which cells generate vital energy molecules like ATP. In the context of liver metabolism, efficient TCA cycle functioning is essential not only for energy homeostasis but also for managing lipid accumulation and oxidative stress—two major factors implicated in MASLD pathogenesis. The study’s authors reveal that post-translational modification of IDH1 by crotonylation substantially boosts its enzymatic activity, thereby accelerating the TCA cycle flux and mitigating the metabolic derangements associated with fat-laden hepatocytes.

Crotonylation is a form of histone modification where a crotonyl group is added to lysine residues on proteins. Traditionally studied in the context of epigenetic regulation, crotonylation’s emerging role in regulating metabolic enzymes represents a paradigm shift in how biochemical modifications influence cellular metabolism. The research team demonstrated that crotonylation of IDH1 specifically enhances the enzyme’s ability to catalyze the oxidative decarboxylation of isocitrate to α-ketoglutarate, an essential step in the TCA cycle that fuels downstream reactions crucial for cellular energy production.

Mechanistic investigations revealed that crotonylated IDH1 undergoes structural changes that increase substrate affinity and catalytic turnover. This fine-tuning of enzymatic activity facilitates improved mitochondrial function and reduces the accumulation of metabolic intermediates that are otherwise dysregulated in MASLD. By maintaining a more robust mitochondrial metabolic flux, crotonylation indirectly curbs lipotoxicity and reduces the oxidative stress burden on hepatocytes, two interrelated processes that aggravate liver injury in MASLD.

Utilizing advanced proteomic techniques, the researchers quantified crotonylation levels in liver tissues derived from MASLD patients and corresponding animal models. Intriguingly, they observed a significant depletion of crotonylation marks on IDH1 in diseased states, correlating with diminished enzyme activity and perturbed TCA cycle dynamics. This discovery suggests that impaired crotonylation could be a contributing factor to the metabolic dysfunction characterizing MASLD and offers a promising biomarker for disease progression.

To further validate their findings, the team engineered mouse models with liver-specific mutations that either mimic constitutive crotonylation or prevent this modification on IDH1. Mice exhibiting enhanced IDH1 crotonylation were remarkably protected from high-fat diet-induced steatosis and subsequent liver inflammation. These animals showed improved biochemical parameters, decreased lipid accumulation, and reduced histopathological signs of MASLD, underscoring the therapeutic potential of modulating crotonylation pathways.

Beyond the liver-specific effects, this discovery may have broader implications for systemic metabolism. Given that the TCA cycle is a central hub for energy metabolism across tissues, augmenting crotonylation of IDH1 or similar metabolic enzymes could represent a novel strategy for treating metabolic syndromes that extend beyond primary liver disease. The research opens up new vistas for drug development aimed at enhancing endogenous protein modifications rather than directly targeting enzyme active sites, a method that could yield higher specificity with fewer adverse effects.

Underlying these biological insights, the team employed innovative biochemical assays and cutting-edge mass spectrometry to trace crotonylation dynamics in living cells under varying metabolic conditions. They revealed that nutrient status and metabolic stress modulate crotonylation levels, suggesting this modification serves as a responsive regulatory mechanism adapting enzymatic activity to cellular energy demands. Such findings highlight the exquisite control cells exert over metabolic fluxes via reversible protein modifications, reshaping current models of metabolic regulation.

An exciting aspect of the research involves the interplay between crotonylation and other post-translational modifications affecting IDH1, such as acetylation and phosphorylation. The complex crosstalk between these modifications appears to fine-tune IDH1’s function in a context-dependent manner, potentially integrating multiple signaling pathways related to nutrient sensing and stress response. Future work disentangling these interactions could provide a comprehensive framework for understanding metabolic enzyme regulation.

The clinical implications of this work are profound. With MASLD on the rise globally due to increasing prevalence of obesity and type 2 diabetes, the identification of modifiable biochemical pathways offers a fresh avenue for therapeutic intervention. Current drugs targeting lipid metabolism or inflammation have had limited success, but targeting crotonylation pathways might circumvent these obstacles by restoring fundamental energy metabolism. Moreover, this approach has the advantage of enhancing endogenous metabolic capacity rather than imposing exogenous interventions that might disrupt systemic balances.

Furthermore, the study’s insights into mitochondrial function shed light on how metabolic flexibility—that is, the ability of cells to adapt energy production pathways in response to diet and environment—can be manipulated for therapeutic benefit. Mitochondrial dysfunction is a hallmark not only of MASLD but many chronic diseases, including neurodegeneration and cancer. Therefore, crotonylation-modulated IDH1 activity might emerge as a universal target in diverse pathologies involving mitochondrial impairment.

Given these promising outcomes, the study paves the way for clinical exploration of agents capable of modulating protein crotonylation. Small molecules that enhance crotonyl-CoA availability or inhibit de-crotonylases could serve as lead compounds for drug development. These therapeutic strategies would differ fundamentally from enzyme inhibitors or receptor modulators, operating instead by augmenting beneficial protein modifications to restore physiology.

This research also prompts a reevaluation of crotonylation’s role in broader epigenetic and metabolic contexts. Its dual role in regulating chromatin structure and enzymatic activity suggests it may coordinate gene expression with metabolic adaptation—a vital process during cellular stress, differentiation, or disease. Deciphering this coordination will have far-reaching implications for biology and medicine.

In sum, the crotonylation of IDH1 represents a vital metabolic checkpoint controlling the progression of MASLD through enhancement of the TCA cycle. By illuminating this molecular mechanism, Liu et al. offer a groundbreaking perspective that bridges epigenetic modification and metabolic control. Their work not only elucidates a novel biological principle but also carves a path toward innovative therapies for one of the most pressing liver disorders of our time.

Subject of Research:
The biochemical modulation of IDH1 via crotonylation and its impact on Metabolic Associated Steatotic Liver Disease (MASLD) progression through enhancement of the tricarboxylic acid cycle.

Article Title:
Crotonylation of IDH1 alleviates MASLD progression by enhancing the TCA cycle.

Article References:
Liu, S., Ji, Y., Wei, L. et al. Crotonylation of IDH1 alleviates MASLD progression by enhancing the TCA cycle. Nat Commun 16, 7961 (2025). https://doi.org/10.1038/s41467-025-62731-9

Image Credits: AI Generated